Respironics CPAP, Inc. is a developer, manufacturer and marketer of medical devices used primarily for the treatment of patients suffering from respiratory disorders.
The Respironics Company's CPAP products are designed to reduce costs, while improving the effectiveness of patient care and are used primarily in the home and in hospitals, along with alternative care facilities and in emergency medical settings.
Its primary CPAP product lines are Homecare CPAP products, such as sleep apnea products, continuous positive airway pressure (CPAP) devices and bi-level positive airway pressure devices used in the home for the treatment of obstructive sleep apnea, a serious disorder characterized by the repeated cessation of breathing during sleep; Respironics CPAP Hospital products, such as therapeutic devices assist or control a patient's ventilation, such as bi-level, non-invasive ventilation products and critical care ventilation products, which deliver both non-invasive and invasive ventilation and cardio-respiratory monitoring products.
The Respironics CPAP company makes respiratory products for use at home, in hospitals, and in emergency situations. Respironics CPAP is a leading maker of devices that treat obstructive sleep apnea (OSA), including its REMstar CPAP (continuous positive airway pressure) system; OSA is a disorder characterized by cessation of breathing during sleep. Other products include invasive and noninvasive ventilators for use in hospitals, at home, or other care facilities; oxygen concentrators; peak-flow meters and drug-delivery systems to treat asthma and allergies; and monitoring systems for sudden infant death syndrome (SIDS).
Respironics CPAP is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and healthcare providers. Respironics markets its products in more than 125 countries and employs over 3,200 associates worldwide.
The Homecare Division gives Respironics CPAP its dominant position in the home respiratory marketplace. Respironics CPAP continues to drive the markets for sleep apnea, infant jaundice and apnea, chronic obstructive pulmonary disease and other respiratory afflictions. The Respironics CPAP Homecare Division holds the number one market share position in most of our product offerings.
This Division of Respironics CPAP has broadened its product offering and distribution in the neonatal and pediatric intensive care units of hospitals and also in the home with the recent acquisition of Children’s Medical Ventures which provides developmental care products and services that improve the quality of care for premature infants.
